Shares of DexCom Inc. DXCM inched 0.89% higher to $78.41 Monday, on what proved to be an all-around grim trading session for ...
Major media outlets are giving wall-to-wall coverage to UnitedHealthcare CEO Brian Thompson’s murder while taking millions in ...
In the assessment of 12-month price targets, analysts unveil insights for DexCom, presenting an average target of $98.44, a ...
BNY Mellon Research Growth Fund (Class A at NAV) underperformed its benchmark, the Russell 1000® Growth Index, during the ...
Canaccord analyst William Plovanic raised the firm’s price target on DexCom (DXCM) to $99 from $89 and keeps a Buy rating on the shares.
Insulet Corporation’s PODD rapid progress with its strategic imperatives on Omnipod platform is poised to help it grow in the upcoming quarters. The largely untapped diabetes market also presents ...